

**Table S1: Demographic patient's data**

<b>Number of patients</b>	13
<b>Age</b> (mean/range)	54.6 years (32-66)
<b>Type of Haemophilia</b>	
<b>A severe</b>	12
<b>A moderate</b>	1
<b>Haemophilia Joint Health Score</b> (mean/range)	Pre-op: 18.4 (16-22)
<b>Inhibitors</b>	8/13 patients
<b>HCV infections</b>	12/13 patients (11 neutralized)
<b>HIV infections</b>	1/13 patients
<b>Previous surgery</b>	9/13 patients
<b>Other target joints</b>	13/13 patients

**Table S2: Surgical and clinical data**

<b>TYPE OF SURGERY</b>	<b>N° of cases</b>	<b>Complications</b>	<b>Transfusions</b>	<b>Mean VAS</b> Pre/post-op	<b>Mean HJHS</b> Pre/post-op	<b>Satisfaction</b>
<b>Total Knee Arthroplasty</b>	5	-	-	8.3 / 1.1	19.5 / 3.0	Full
<b>Total Hip Arthroplasty</b>	2	-	-	9.1 / 0.8	21.2 / 2.5	Full
<b>Revision Knee Arthroplasty</b>	2	-	-	7.5 / 1.3	18.7 / 3.6	Full
<b>Revision Hip Arthroplasty</b>	3	-	2	7.1 / 1.0	19.0 / 3.1	Full
<b>Pseudotumor excision</b>	2	1 (recurrence of infection)	-	6.4 / 2.4	16.6 / 5.3	Full (1) / Partial (1)
<b>Amputation</b>	1	-	-	7 / 3	22.0 / 10.4	-

Table S3: Comparative results of specific series

Authors & publication year	N° of major orthopaedic surgeries	Type of Haemophilia & Haematological prophylaxis	Follow-up	Complications
Seaman and Ragni, 2019	1 Total Hip Arthroplasty	Mild Haemophilia A and high-titre inhibitors  Emicizumab & rFVIIa	2 weeks	None
Evans et al, 2020	1 Revision Total Knee Arthroplasty (after an infected TKA)	Severe Haemophilia A and high-titre inhibitors  Emicizumab & rFVIIa	1 month	Bleeding during the first day of post-operative rehabilitation
Guillaume et al, 2021	1 Total Elbow Arthroplasty	Severe Haemophilia A  Emicizumab & rFVIII	5 days	None
Renner et al, 2023	5 patients (8 procedures): - 4 fixations (1 bilateral) - 1 Total Knee Arthroplasty - 2 below-the-knee amputations - 1 necrectomy after new ankle fusion	Severe Haemophilia A (4 cases) Severe Haemophilia A and high-titre inhibitors (1 cases)  Emicizumab & rFVIII (no inh) or Emicizumab & rFVIIa (inh)	About 3 years	<ul style="list-style-type: none"> <li>• 1 severe bleeding in the third day of post-operative rehabilitation needing further surgery (finally, a below-the-knee amputation)</li> <li>• 1 infection (Total Knee Arthroplasty)</li> <li>• 1 infection after ankle fusion (finally, a below-the-knee amputation)</li> <li>• Further surgery after a femoral fracture non-union</li> </ul>
Present study	13 patients (15 procedures): - 5 Total Knee Arthroplasties - 2 Total Hip Arthroplasties - 2 revision TKAs - 3 revision THAs - 2 pseudotumor excisions - 1 above-the-knee amputation	Severe Haemophilia A (cases) Severe Haemophilia A and high-titre inhibitors (x cases)  Emicizumab & rFVIII (no inh)  Emicizumab & rFVIIa (inh)	More than 3 years	3 blood transfusions: <ul style="list-style-type: none"> <li>• 2 after 2 revision THA</li> <li>• 1 after an above-the-knee amputation</li> </ul>